查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球小分子CDMO的成長機會
市場調查報告書
商品編碼
1319192

全球小分子CDMO的成長機會

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities
出版日期: | 出版商: Frost & Sullivan | 英文 86 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

正確的支撐和標靶治療創造未來成長

CDMO（契約開發和製造組織）是外包藥物開發和製造服務的第三方供應商。在小分子藥物製造領域，CDMO提供專業的開發和製造服務，現已成為製藥行業價值鏈不可或缺的一部分。

慢性病患病率的不斷上升增加了對創新小分子藥物的需求。製藥行業致力於開發新穎、更有效的靶向療法，導致產品線不斷成長，對創新藥物輸送方法的需求也不斷成長。與此同時，中小型製藥公司負責其研發管線中70%以上的藥物，但往往缺乏將其臨床管線推向市場的專業知識。

Frost & Sullivan 預計，由於對小分子口服固體劑型、標靶藥物給藥技術、強效和高活性藥物以及其他複雜分子的需求不斷增加，預測期內將出現持續成長。能夠提供技術領先、靈活性、模組化製造專業知識、端到端能力和能力以及創新藥物輸送技術的 CDMO 將成為首選合作夥伴。為了推動成長，CDMO 將繼續優先考慮製造流程各個方面的創新、協作、擴張、自動化和最佳化。

本報告分析了全球小分子 CDMO 市場。分析期為2021-2028年，其中2022年為基準年，2023-2028年為預測期。根據產品類型，大致分為原料藥（API）/藥品製造和成品藥（FDF）/藥品製造。此外，API分為創新藥和學名藥，FDF分為口服劑型、半固體/液體劑型和注射劑型。

最重要的是，本報告根據小分子 CDMO 市場不斷變化的需求和創新、標靶治療、高活性 API 和複雜藥物的出現，強調了各種規模的進入者的商機。

調查亮點

  • 按細分市場和地區分類的盈利預測（北美、歐洲、亞太地區、世界其他地區）
  • 主要進入者的市場佔有率、市場整合和業務擴張努力、服務產品和業務模式演變
  • 影響 CDMO 選擇的因素
  • CDMO 致力於永續性和靈活的製造專業知識

目錄

戰略問題

  • 為什麼成長如此困難？
  • The Strategic Imperative 8 (TM)
  • 全球小分子 CDMO 行業的戰略問題：三大影響
  • 成長管道引擎 (TM)：成長機會加速

成長機會分析

  • 分析範圍
  • 按產品類型細分
  • 按服務類型細分
  • 主要競爭
  • 成長指數
  • 成長促進因素
  • 生長抑制因素
  • 預測框架：市場規模
  • 調查方法
  • 預測假設
  • 收入預測
  • 收入預測分析
  • 按地區分類的收入預測
  • 按地區分類的收入預測分析
  • 按產品類型分類的收入預測
  • 按產品類型分類的收入預測分析
  • 按服務類型分類的收入佔有率預測
  • 按服務類型分類的收入佔有率預測分析
  • 競爭環境
  • 收入佔有率
  • 收入佔有率分析

成長環境

  • 小分子藥物與生物製劑的批准比較
  • 小分子市場展望：主要治療領域和劑型
  • 不斷成長的管道和產品創新
  • 構建 HPAPI 專業知識以實現精準醫療
  • 擴展 CDMO 價值鏈：過渡到 CRDMO 模式
  • 擴展 CDMO 價值鏈：全面的端到端產品
  • 支持向 CRDMO 模式過渡的努力
  • 向商業模式轉型的能力演進：從計畫型到綜合長期模式
  • 影響 CDMO 選擇的因素
  • 影響 CDMO 選擇的因素：分析
  • 以 ESG 為重點的舉措，成為首選合作夥伴
  • 小分子 CDMO 行業的整合步驟
  • 透過利用規模和擴大投資組合來努力擴張
  • 塑造小分子 CDMO 行業的成長趨勢：總結

成長機會分析：API（活性藥物成分）

  • 成長指標
  • 盈利和預測
  • 按產品類型分類的收入預測
  • 預測分析

成長機會分析：FDF（成品配方）

  • 成長指數
  • 收入預測
  • 按產品類型分類的收入預測
  • 預測分析：口服藥物
  • 預測分析：注射劑
  • 預測分析：液體/半固體配方
  • 預測分析：其他

成長機會宇宙

  • 成長機會1：BA 增強型 OSD 配方解決方案
  • 成長機會2：標靶治療藥物的放射性藥物製造
  • 成長機會3：用於系列化的創新互聯包裝解決方案
  • 成長機會4：差異化注射專用學名藥的能力

下一步

  • 下一步
  • 現在為何選擇 Frost & Sullivan？
  • 附件清單
  • 免責聲明
簡介目錄
Product Code: PEA0-52

Right Shoring and Targeted Therapeutics Create Future Growth

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain.

The growing incidence of chronic diseases propels the demand for innovative small-molecule medicines. The pharmaceutical industry's focus on developing novel, more efficacious, and targeted therapies has resulted in increased product pipelines and the need for innovative drug delivery methods. Simultaneously, while small and mid-sized pharma companies are responsible for over 70% of drugs in the R&D pipeline, they often lack the expertise to bring their clinical pipeline to market.

Frost & Sullivan expects sustained growth during the forecast period, driven by increasing demand for small molecules in oral solid formulations, targeted drug delivery technologies, potent and highly potent drugs, and other complex molecules. CDMOs equipped to provide technological leadership, flexibility, expertise for modular manufacturing, end-to-end capabilities and capacities, and innovative drug delivery technologies will likely emerge as the partner of choice. To drive growth, CDMOs will continue prioritizing innovation, collaboration, expansion, automation, and optimization across all aspects of the manufacturing process.

In this report, Frost & Sullivan overviews the global small-molecule CDMO market. The study period is 2021-2028, with 2022 as the base year and 2023-2028 as the forecast period. We segment the study into two main categories based on the product type: active pharmaceutical ingredients (API)/drug substance manufacturing and fixed dosage form (FDF)/drug product manufacturing. Frost & Sullivan segments API further into innovator and generic and FDF into oral, semisolid/liquid, and injectables.

Most importantly, the report highlights opportunities for participants of all sizes based on the evolving needs and innovations in the small-molecule CDMO market, the emergence of targeted therapeutics, highly potent APIs, and complex drugs.

Research Highlights

  • Revenue forecasts by segment and region (North America, Europe, Asia-Pacific, and the Rest of the World)
  • Market share of leading participants, consolidation and expansion initiatives, and developments in service offerings and business models
  • Factors influencing CDMO selection
  • CDMOs’ focus on sustainability and flexible manufacturing expertise

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Small Molecule CDMO Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation by Product Type
  • Segmentation by Service Type
  • Key Competitors
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Framework: Market Sizing
  • Forecast Methodology
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Analysis
  • Revenue Forecast by Region
  • Revenue Forecast Analysis by Region
  • Revenue Forecast by Product Type
  • Revenue Forecast Analysis by Product Type
  • Revenue Share Forecast by Service Type
  • Revenue Share Forecast Analysis by Service Type
  • Competitive Environment
  • Revenue Share
  • Revenue Share Analysis

Growth Environment

  • Comparison Between Small Molecules and Biologics Approvals
  • Small Molecule Market Outlook: Main Therapy Area and Dosage Form
  • Growing Pipeline and Product Innovation
  • Building Expertise in HPAPI Enabling Precision Medicine
  • Expanding the CDMO Value Chain: Transition to a CRDMO Model
  • Expanding the CDMO Value Chain: Comprehensive End-to-end Offering
  • Initiatives Supporting Transition to the CRDMO Model
  • Capability Evolution for Transitioning the Business Model from Project-based to Integrated Long-term
  • Factors Influencing CDMO Selection
  • Factors Influencing CDMO Selection: Analysis
  • ESG-focused Initiatives to Become a Partner-of-Choice
  • Consolidation Steps in the Small Molecule CDMO Industry
  • Expansion Initiatives to Capitalize on Scale and Broadening Portfolio
  • Summary of Growth Trends Shaping the Small Molecule CDMO Industry

Growth Opportunity Analysis: API

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Forecast Analysis

Growth Opportunity Analysis: FDF

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Forecast Analysis: Oral
  • Forecast Analysis: Injectable
  • Forecast Analysis: Liquids/Semisolids
  • Forecast Analysis: Others

Growth Opportunity Universe

  • Growth Opportunity 1: BA Enhancement Solutions for OSD Formulation
  • Growth Opportunity 2: Radiopharmaceutical Manufacturing for Targeted Therapeutics
  • Growth Opportunity 3: Innovative and Connected Packaging Solutions for Serialization
  • Growth Opportunity 4: Differentiated Capabilities for Injectable Specialty Generics

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer